Oncobox GTM brain

category

market profile

• text: The product analyzes tumor DNA and RNA and presents a ranked drug report to physicians or a medical board.
• text: A published prospective study evaluated RNA-based drug ranking in adult solid tumors; the paper notes sample timing affected predictive capacity, so clinical applicability needs case-specific review.
• text: Precision oncology competitors also use tumor molecular profiling to match patients to targeted therapies and trials, though assays differ.

personas

• title: Medical oncologist
  pains:

  • Selecting a subsequent treatment for a patient whose cancer has progressed remains difficult
  • Molecular findings require interpretation alongside clinical history and evidence
• title: Molecular tumor board lead
  pains:

  • The team needs an interpretable view linking tumor molecular changes to possible drugs
  • Evidence must be assessed for the patient's cancer type and treatment setting
• title: Oncology laboratory or clinic partnerships director
  pains:

  • Specimen collection, profiling and delivery of results must fit the clinical workflow
  • Clinicians need clarity on access, validation and turnaround before offering testing

icp

• text: Cancer hospitals and oncology practices managing advanced solid tumor cases and considering molecular profiling.
• text: Clinics and genomic laboratories able to coordinate tumor samples and clinical interpretation with affiliated physicians.

message pillars

• text: Combine DNA and RNA analysis from a tumor sample.
• text: Generate an individualized ranking of therapies.
• text: Present molecular findings and trial outcomes in the report.

objections

• objection: Is there evidence the ranking improves outcomes for our patients?
  response: Review study design, cancer subtype, sample timing and endpoints with the treating team; findings should not be assumed to generalize.
• objection: How is testing obtained and integrated into care?
  response: The company describes access via affiliated clinics and tumor sample submission; confirm local availability, turnaround and regulatory status.
• objection: What will the test cost and will insurance cover it?
  response: Request a current quote and payer coverage details; current pricing was not verified.

competitors

• name: Foundation Medicine
  why: Offers tumor genomic profiling used for therapy and clinical trial selection.
• name: OncoDNA
  why: Provides molecular and theranostic profiling for precision oncology.
• name: Tempus AI
  why: Offers cancer molecular profiling and data tools for treatment decisions.

keywords

• tumor molecular profiling
• precision oncology testing
• cancer RNA sequencing
• targeted therapy selection
• molecular tumor board
• cancer drug ranking

voice

• Clinical and science-led
• Optimistic about personalized treatment

signals

• text: A cancer center is building molecular tumor board capacity or considering RNA sequencing for advanced cancer cases.
• text: An oncology clinic is seeking a partner to process tumor specimens and deliver molecular reports.

pricing

motion

channels

• clinical research publications
• clinic partnerships

confidence

Founders

• name: Andrew Garazha
  title: Founder/CEO
  role: CEO
• name: Anton Buzdin
  title: Founder/CSO
  role: Founder